3-Pyridinecarboxamide, 5-chloro-6-[(3S)-4-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-N-ethyl- manufacturers
- VUF11211
-
- $1980.00
-
2026-07-27
- CAS:906556-51-2
- Purity:
- Supply Ability: 10g
|
| | 3-Pyridinecarboxamide, 5-chloro-6-[(3S)-4-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-N-ethyl- Basic information |
| | 3-Pyridinecarboxamide, 5-chloro-6-[(3S)-4-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-N-ethyl- Chemical Properties |
| Boiling point | 621.4±55.0 °C(Predicted) | | density | 1.219±0.06 g/cm3(Predicted) | | pka | 13.60±0.46(Predicted) |
| | 3-Pyridinecarboxamide, 5-chloro-6-[(3S)-4-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-N-ethyl- Usage And Synthesis |
| Description | VUF11211 is a potent CXCR3 antagonist. It acts by extending from the minor pocket into the major pocket of the transmembrane domains and binding between residues in helices 1 (Y1.39), 2 (W2.60), 3 (F3.32), 4 (D4.60), 6 (Y6.51), and 7 (S7.39, Y7.43). | | Uses | VUF11211 is an allosteric inverse CXCR3 agonist with a Kd of 0.65 nM[1]. | | References | [1] Scholten DJ, et al. Pharmacological characterization of [3H]VUF11211, a novel radiolabeled small-molecule inverse agonist for the chemokine receptor CXCR3. Mol Pharmacol. 2015 Apr;87(4):639-48. DOI:10.1124/mol.114.095265 |
| | 3-Pyridinecarboxamide, 5-chloro-6-[(3S)-4-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-3-ethyl-1-piperazinyl]-N-ethyl- Preparation Products And Raw materials |
|